Posted by Michael Wonder on 15 May 2019
NHS chief hails SMA drug deal – and was that a swipe at Vertex?
15 May 2019 - Children in England with the rare muscle wasting disease spinal muscular atrophy will get access to Biogen’s super-expensive new drug Spinraza after the manufacturer struck a deal with NHS officials.
NHS England chief executive Simon Stevens endorsed the agreement, adding what looked like a swipe at Vertex, which has been rowing with the NHS for nearly three years over the price of its cystic fibrosis drugs.
Vertex has gone as far as refusing to send files to NICE for cost-effectiveness assessments, saying that the health system in England hugely undervalues its drugs.
